December 14, 2012
Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.
In this week's installment, Johnson & Johnson's (NYSE: JNJ ) fastest growing drug Zytiga was approved Monday by the FDA for a pre-chemo indication. While this was largely expected, this is a major step for the drug, as the pre-chemo indication is much bigger than the indication as a second line treatment. In this video, Motley Fool health-care analyst Brenton Flynn tells us what this means for the company and the drug from here.
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.